BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...of the company’s total sales. Checkpoint combinations could change Imlygic’s trajectory. Øystein Soug, CEO of Targovax A/S...
...with HSV therapies include Replimune, Oncorus Inc. and Virogen. Adenovirus companies include Cold Genesys and Targovax...
...in the virus to turn the patient into a small factory for the drug,” said Targovax’s...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...stood down in December. Vink was COO at Cubist Pharmaceuticals Inc. Vink is chairman of Targovax A/S...
BioCentury | May 11, 2018
Clinical News

Targovax reports Phase I/II data for ONCOS-102 in mesothelioma

...alone. ONCOS-102 is a modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF. Targovax A/S...
...ORR), progression-free survival (PFS) and overall survival (OS) Status: Phase I/II data Milestone: NA Sandi Wong ONCOS-102, cgtg-102 Targovax A/S...
BioCentury | Feb 2, 2018
Clinical News

Targovax reports Phase I data for ONCOS-102 in melanoma

...then received Keytruda at week three and every three weeks for up to 24 weeks. Targovax...
...to treat unresectable malignant pleural mesothelioma and Phase I/II testing to treat advanced peritoneal malignancies. Targovax A/S...
...benefit rate (CBR) and change in individual lesion size Status: Phase I data Milestone: NA Allison Johnson ONCOS-102 Targovax A/S...
BioCentury | Jun 2, 2017
Clinical News

Targovax reports OS data for TG01 vaccine in pancreatic cancer

...In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Targovax A/S...
...endpoints include disease-free survival (DFS), OS and the relationship between K-Ras (KRAS) status and recurrence. Targovax...
...March 14, 2016 ). TG01 is a peptide vaccine targeting Ras mutations associated with cancer. Targovax A/S...
BioCentury | May 17, 2017
Clinical News

Targovax starts Phase Ib of ONCOS-102 in melanoma

...rate. ONCOS-102 is a modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF. Targovax A/S...
...at lesions and in peripheral blood; clinical response rate Status: Phase Ib started Milestone: NA Julian Zhu ONCOS-102 Targovax A/S...
BioCentury | May 2, 2017
Clinical News

Targovax starts Ph Ib of TG02 in rectal cancer

...tumor marker carcinoembryonic antigen (CEA). TG02 comprises 8 synthetic peptides representing fragments of Ras mutations. Targovax A/S...
...standard uptake values and tumor marker carcinoembryonic antigen (CEA) Status: Phase Ib started Milestone: NA Julian Zhu TG02 Targovax A/S...
BioCentury | Jul 18, 2016
Clinical News

ONCOS-102: Phase Ib/II started

...about 30 patients. This half, Targovax plans to begin 3 additional combination trials with ONCOS-102. Targovax A/S...
BioCentury | Jul 14, 2016
Product R&D

Agonistic families

...Gene therapy vectors engineered to express TNF family proteins can stimulate an antitumor immune response. Targovax A/S...
...Turnhout, Belgium Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Targovax A/S...
BioCentury | Jul 11, 2016
Clinical News

TG01: Completed Phase I/II enrollment

...from the trial (see BioCentury, Feb. 17, 2014; July 20, 2015 & March 14, 2016). Targovax A/S...
Items per page:
1 - 10 of 24
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...of the company’s total sales. Checkpoint combinations could change Imlygic’s trajectory. Øystein Soug, CEO of Targovax A/S...
...with HSV therapies include Replimune, Oncorus Inc. and Virogen. Adenovirus companies include Cold Genesys and Targovax...
...in the virus to turn the patient into a small factory for the drug,” said Targovax’s...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...stood down in December. Vink was COO at Cubist Pharmaceuticals Inc. Vink is chairman of Targovax A/S...
BioCentury | May 11, 2018
Clinical News

Targovax reports Phase I/II data for ONCOS-102 in mesothelioma

...alone. ONCOS-102 is a modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF. Targovax A/S...
...ORR), progression-free survival (PFS) and overall survival (OS) Status: Phase I/II data Milestone: NA Sandi Wong ONCOS-102, cgtg-102 Targovax A/S...
BioCentury | Feb 2, 2018
Clinical News

Targovax reports Phase I data for ONCOS-102 in melanoma

...then received Keytruda at week three and every three weeks for up to 24 weeks. Targovax...
...to treat unresectable malignant pleural mesothelioma and Phase I/II testing to treat advanced peritoneal malignancies. Targovax A/S...
...benefit rate (CBR) and change in individual lesion size Status: Phase I data Milestone: NA Allison Johnson ONCOS-102 Targovax A/S...
BioCentury | Jun 2, 2017
Clinical News

Targovax reports OS data for TG01 vaccine in pancreatic cancer

...In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Targovax A/S...
...endpoints include disease-free survival (DFS), OS and the relationship between K-Ras (KRAS) status and recurrence. Targovax...
...March 14, 2016 ). TG01 is a peptide vaccine targeting Ras mutations associated with cancer. Targovax A/S...
BioCentury | May 17, 2017
Clinical News

Targovax starts Phase Ib of ONCOS-102 in melanoma

...rate. ONCOS-102 is a modified tumor-targeted human serotype 5/3 adenovirus carrying the gene for GM-CSF. Targovax A/S...
...at lesions and in peripheral blood; clinical response rate Status: Phase Ib started Milestone: NA Julian Zhu ONCOS-102 Targovax A/S...
BioCentury | May 2, 2017
Clinical News

Targovax starts Ph Ib of TG02 in rectal cancer

...tumor marker carcinoembryonic antigen (CEA). TG02 comprises 8 synthetic peptides representing fragments of Ras mutations. Targovax A/S...
...standard uptake values and tumor marker carcinoembryonic antigen (CEA) Status: Phase Ib started Milestone: NA Julian Zhu TG02 Targovax A/S...
BioCentury | Jul 18, 2016
Clinical News

ONCOS-102: Phase Ib/II started

...about 30 patients. This half, Targovax plans to begin 3 additional combination trials with ONCOS-102. Targovax A/S...
BioCentury | Jul 14, 2016
Product R&D

Agonistic families

...Gene therapy vectors engineered to express TNF family proteins can stimulate an antitumor immune response. Targovax A/S...
...Turnhout, Belgium Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Targovax A/S...
BioCentury | Jul 11, 2016
Clinical News

TG01: Completed Phase I/II enrollment

...from the trial (see BioCentury, Feb. 17, 2014; July 20, 2015 & March 14, 2016). Targovax A/S...
Items per page:
1 - 10 of 24